Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
NCT ID: NCT01323998
Last Updated: 2017-07-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
35032 participants
OBSERVATIONAL
2010-04-30
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
NCT01332487
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
NCT01386983
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
NCT01435954
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
NCT01376258
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
NCT01334723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
5ARI monotherapy
Patients with BPH receiving 5ARI monotherapy
5ARI
Dutasteride or Finasteride
AB monotherapy
Patients with BPH receiving AB monotherapy
AB
Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Early combination (5ARI + AB) therapy
Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
5ARI
Dutasteride or Finasteride
AB
Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Delayed combination (5ARI + AB) therapy
Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
5ARI
Dutasteride or Finasteride
AB
Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5ARI
Dutasteride or Finasteride
AB
Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 50 years or older
* a diagnostic claim for BPH
* at least one prescription claim for a 5ARI or AB in the enrollment period
* continuous eligibility for 6 months prior to and 12 months after index prescription date
Exclusion Criteria
* any prostate-related surgical procedure within 1 month of the index prescription date
* prescription claim for finasteride 1 mg for male pattern baldness during the study period
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
114462
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.